Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. filed a report to share an updated June 2026 corporate presentation highlighting its immuno-oncology pipeline and financial position. The company is developing CAPTN-3, a tri-specific antibody platform that engages both T cells and NK cells using a masking technology designed to improve safety while maintaining anti-tumor activity.
Lead candidate IM1240 (capped CD3 x 5T4 x NKG2A) is expected to enter first-in-human trials in 2027, with a Phase 1 study planned across several 5T4-expressing solid tumors and a key catalyst from study results starting from the first half of 2028. Preclinical data show up to 300-fold higher tolerated dosing versus a non-capped comparator and dose-proportional pharmacokinetics in non-human primates.
The presentation also describes second CAPTN-3 program IM1305 (capped CD3 x TROP2 x NKG2A), antibody CM24 targeting CEACAM1 with Phase 2 proof-of-concept data in pancreatic cancer, and small-molecule NT219 targeting IRS1/2 and STAT3 in head and neck cancer. As of March 31, 2026, Purple Biotech reported cash of $6.4 million, which it states provides runway into the first half of 2027.
Purple Biotech Ltd. reported new preclinical results for its lead CAPTN-3 candidate IM1240, presented at the EACR 2026 cancer research congress. In non-human primates, a toxicology study showed IM1240 had an 8-fold longer half-life, 16-fold greater exposure and a markedly improved cytokine-release safety profile versus a non-capped variant, supporting a broad therapeutic window and plans to move into first-in-human testing in 2027.
IM1240 demonstrated anti-tumor activity in patient-derived tumors resistant to PD-1 and standard chemotherapy across head and neck, bladder and lung cancers, with the NKG2A arm identified as critical for efficacy. In non-small cell lung cancer explants, IM1240 triggered immune remodeling, including formation of mature tertiary lymphoid structures, increased CD8 T and NK cells, and reduced regulatory T cells, consistent with effective anti-tumor immune responses.
Purple Biotech Ltd. filed a Form F-3 registration statement to register up to $200,000,000 of securities under a shelf offering.
The registration specifically includes an at-the-market program under a Sales Agreement with H.C. Wainwright for up to $824,331 of ADSs; the ADS ratio is 1 ADS = 2,000 ordinary shares. The company reports a public float of approximately $4.9 million.
Purple Biotech Ltd. reported first quarter 2026 results and business updates centered on its CAPTN-3 tri-specific antibody platform. Research and development expenses were $1.2 million, up from $0.8 million a year earlier, mainly from increased CMC work on CAPTN-3. General and administrative expenses rose to $1.0 million from $0.6 million.
Adjusted operating loss was $2.1 million versus $1.3 million in 2025, while net loss narrowed to $0.1 million, helped by $2.2 million of finance income driven by warrant fair-value changes. Adjusted net loss was $2.1 million. Cash, cash equivalents and short-term deposits totaled $6.4 million as of March 31, 2026, which management expects will fund operations into 2027, as the company advances IM1240 and IM1305 toward first-in-human studies.
Purple Biotech Ltd. reports beneficial ownership filings by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC showing 282,513,535 Ordinary Shares issuable upon exercise of an Intracoastal warrant, representing 9.99% of the class.
The filing states the 9.99% figure is based on 2,545,449,780 Ordinary Shares outstanding as of March 18, 2026 plus the 282,513,535 shares issuable on the Intracoastal Warrant. A blocker provision prevents exercise of an additional 117,486,465 shares that would otherwise increase beneficial ownership to 400,000,000.
Purple Biotech Ltd. reported new preclinical results for IM1240, the lead tri-specific antibody from its CAPTN-3 platform. In lab studies run at the Icahn School of Medicine at Mount Sinai, all seven tested patient-derived, treatment-resistant tumor samples responded to IM1240.
The data highlight the role of IM1240’s NKG2A arm: when this binding domain was mutated, apoptotic activity was lost across all samples, underscoring its contribution to anti-tumor effects. In a non-small cell lung cancer biopsy, IM1240 also induced mature tertiary lymphoid structures and increased CD8 T cells and NK cells while reducing Tregs and tumor cells.
The company describes CAPTN-3 as a platform of masked tri-specific antibodies designed to activate T cells and NK cells selectively in the tumor microenvironment. IM1240 and a second candidate, IM1305, remain in preclinical development, while other assets CM24 and NT219 are at clinical stage pending further partnering or investment.
Purple Biotech Ltd. reported that it has established a Scientific Advisory Board (SAB) to guide development of its CAPTN-3 tri-specific antibody immunotherapy platform. The SAB includes experts in T-cell engagers, NK and T cell biology, tumor immunology and clinical oncology, including leaders involved in foundational approved therapies.
CAPTN-3 is a platform of masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells, using proprietary capping technology to confine immune activation to the tumor microenvironment. Lead candidate IM1240 is advancing toward the clinic, while IM1305 remains in preclinical development.
Purple Biotech also highlights additional pipeline assets: CM24, a CEACAM1-blocking antibody that showed improved outcomes across all efficacy endpoints in a Phase 2 pancreatic ductal adenocarcinoma study, and NT219, a dual IRS1/2 and STAT3 inhibitor in a Phase 2 study for head and neck cancer.
PURPLE BIOTECH LTD. director Simcha Rock filed an initial ownership statement showing substantial equity-based compensation. He directly holds 3,207,690 Ordinary Shares, including 2,454,167 unvested restricted stock units that settle in shares. He also holds stock options to buy 300,000 shares at $0.059375 per share and 2,650,000 shares at $0.00309375 per share, with vesting schedules running through 2028 and expirations in 2028 and 2030. Each American Depositary Share currently represents 2,000 Ordinary Shares.
PURPLE BIOTECH LTD. director Suzana Zilberberg filed an initial ownership report showing her equity stake in the company. She directly holds 3,062,500 Ordinary Shares as of the reported date, including 2,454,167 unvested restricted stock units that will settle in Ordinary Shares.
She also holds stock options to purchase 112,500 Ordinary Shares at $0.126875 per share expiring on December 29, 2026, options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028, and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with portions of these options vesting over time.
PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure. He beneficially owns 3,093,860 Ordinary Shares, including 2,454,167 unvested RSUs that settle in Ordinary Shares, and holds stock options over an additional 2,950,000 Ordinary Shares at low exercise prices.